COMMUNIQUÉS West-GlobeNewswire
-
Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market
21/07/2026 -
Vaxart to Participate in BTIG Biotechnology Conference 2026
21/07/2026 -
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
21/07/2026 -
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
21/07/2026 -
Philips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor
21/07/2026 -
Nelipak Releases 2025 Sustainability Report
21/07/2026 -
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
21/07/2026 -
Standard Dental Labs Announces Acquisition Capital Strategy to Support Next Phase of Florida Expansion
21/07/2026 -
SK pharmteco and Genethon Showcase French Manufacturing Strength Behind Pivotal DMD Gene Therapy Program
21/07/2026 -
Merakris Therapeutics Awarded NIH Direct-to-Phase II SBIR Grant to Advance MTX-001 for Diabetic Foot Ulcers
21/07/2026 -
Exagen to Announce Second Quarter Financial Results on August 4, 2026
21/07/2026 -
Beacon Behavioral Partners Enters Michigan and Ohio Through Partnership with Pure Psychiatry
21/07/2026 -
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
21/07/2026 -
Three Peat: USOSM Recognized as One of the Region’s Fastest Growing Companies by Dallas Business Journal
21/07/2026 -
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
21/07/2026 -
PatientsLikeMe and Science 37 Partner to Unlock Trial Access for Interested, Eligible Patients
21/07/2026 -
NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD
21/07/2026 -
SkinHealth Systems to Report Second Quarter 2026 Financial Results on August 6, 2026
21/07/2026 -
Revagenix Expands Executive Team, Names Peter Smith, Ph.D., Chief Scientific Officer as Lead Program Enters the Clinic
21/07/2026
Pages